Cancer Res Treat.  2022 Apr;54(2):375-382. 10.4143/crt.2021.449.

Attitudes toward Risk-Reducing Mastectomy and Risk-Reducing Salpingo-oophorectomy among Young, Unmarried, Healthy Women in Korea

Affiliations
  • 1Department of Preventive Medicine, Hanyang University College of Medicine, Seoul, Korea
  • 2Department of Surgery, Daerim St. Mary’s Hospital, Seoul, Korea
  • 3Department of Health Sciences, Hanyang University College of Medicine, Seoul, Korea

Abstract

Purpose
This study investigated the attitudes toward risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO) as cancer prevention options for BRCA1/2 carriers in healthy, young, unmarried Korean women.
Materials and Methods
A nationally representative sample of 600 women, aged 20-39 years, completed a questionnaire on sociodemographic variables, preference for genetic testing, and intention to undergo risk-reducing surgeries after receiving information on the cancer risk of BRCA1/2 mutations and benefits of risk-reducing surgeries.
Results
A total of 54.7% and 57.7% had the intention to undergo RRM and RRSO, respectively, on the assumption that they were BRCA1/2 carriers. Older age and no intention to undergo genetic testing were associated with a reduced likelihood of undergoing RRM (odds ratio [OR], 0.30; 95% confidence interval [CI], 0.14 to 0.61 for age 35-39 years and OR, 0.35; 95% CI, 0.20 to 0.62 for no intention for genetic testing) and RRSO (OR, 0.39; 95% CI, 0.19 to 0.79 for age 35-39 years and OR, 0.30; 95% CI, 0.17 to 0.53 for no intention for genetic testing). Women who chose to be single were likely to undergo risk-reducing surgeries (OR, 1.67; 95% CI, 1.07 to 2.60 for RRM and OR, 1.56; 95% CI, 1.00 to 2.44 for RRSO).
Conclusion
More than 50% of healthy, unmarried, young Korean women were inclined to undergo prophylactic surgeries if they were BRCA1/2 mutation carriers. Further studies on decision-making process for cancer prevention in individuals at high risk for cancer need to be conducted.

Keyword

mutation; Risk-reducing mastectomy; Risk-reducing salpingo-oophorectomy

Reference

References

1. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007; 25:1329–33.
2. Park B, Dowty JG, Ahn C, Win AK, Kim SW, Lee MH, et al. Breast cancer risk for Korean women with germline mutations in BRCA1 and BRCA2. Breast Cancer Res Treat. 2015; 152:659–65.
Article
3. Mauer C, Spencer S, Dungan J, Hurley K. Exploration of male attitudes on partnerships and sexuality with female BRCA1/2 mutation carriers. J Genet Couns. 2016; 25:290–7.
Article
4. Pearce CL, Stram DO, Ness RB, Stram DA, Roman LD, Templeman C, et al. Population distribution of lifetime risk of ovarian cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2015; 24:671–6.
Article
5. Smith KR, Ellington L, Chan AY, Croyle RT, Botkin JR. Fertility intentions following testing for a BRCA1 gene mutation. Cancer Epidemiol Biomarkers Prev. 2004; 13:733–40.
6. Borzekowski DL, Guan Y, Smith KC, Erby LH, Roter DL. The Angelina effect: immediate reach, grasp, and impact of going public. Genet Med. 2014; 16:516–21.
Article
7. Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer. 2019; 121:15–21.
Article
8. Lee J, Kim S, Kang E, Park S, Kim Z, Lee MH, et al. Influence of the Angelina Jolie announcement and insurance reimbursement on practice patterns for hereditary breast cancer. J Breast Cancer. 2017; 20:203–7.
Article
9. Jung SM, Ryu JM, Park HS, Park JS, Kang E, Lee S, et al. Trends in risk-reducing mastectomy and risk-reducing salpingo-oophorectomy in Korean carriers of the BRCA1/2 mutation. J Breast Cancer. 2020; 23:647–55.
Article
10. Calabro GE, Sassano M, Tognetto A, Boccia S. Citizens’ attitudes, knowledge, and educational needs in the field of omics sciences: a systematic literature review. Front Genet. 2020; 11:570649.
11. Gavaruzzi T, Tasso A, Franiuk M, Varesco L, Lotto L. A psychological perspective on factors predicting prophylactic salpingo-oophorectomy in a sample of Italian women from the general population: results from a hypothetical study in the context of BRCA mutations. J Genet Couns. 2017; 26:1144–52.
Article
12. Tong A, Kelly S, Nusbaum R, Graves K, Peshkin BN, Valdimarsdottir HB, et al. Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling. Psychooncology. 2015; 24:33–9.
Article
13. Yoon HY, Shim JS, Lee JW. Perceptions of prophylactic mastectomy in Korea. Arch Plast Surg. 2016; 43:53–8.
Article
14. Ladd MK, Peshkin BN, Senter L, Baldinger S, Isaacs C, Segal H, et al. Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer. Transl Behav Med. 2020; 10:337–46.
Article
15. Mansfield CA, Metcalfe KA, Snyder C, Lindeman GJ, Posner J, Friedman S, et al. Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation. Hered Cancer Clin Pract. 2020; 18:20.
Article
16. Singh K, Lester J, Karlan B, Bresee C, Geva T, Gordon O. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers. Am J Obstet Gynecol. 2013; 208:329.
Article
17. Skytte AB, Gerdes AM, Andersen MK, Sunde L, Brondum-Nielsen K, Waldstrom M, et al. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clin Genet. 2010; 77:342–9.
Article
18. Grann VR, Jacobson JS, Thomason D, Hershman D, Heitjan DF, Neugut AI. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol. 2002; 20:2520–9.
19. Manchanda R, Burnell M, Abdelraheim A, Johnson M, Sharma A, Benjamin E, et al. Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis. BJOG. 2012; 119:527–36.
Article
20. Kim D, Kang E, Hwang E, Sun Y, Hwang Y, Yom CK, et al. Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation. Fam Cancer. 2013; 12:621–8.
Article
21. Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, et al. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer. 2007; 7:875–82.
Article
22. Stuckey A, Dizon D, Scalia Wilbur J, Kent J, Tejada-Berges T, Gass J, et al. Clinical characteristics and choices regarding risk-reducing surgery in BRCA mutation carriers. Gynecol Obstet Invest. 2010; 69:270–3.
Article
23. Howard-McNatt M, Schroll RW, Hurt GJ, Levine EA. Contralateral prophylactic mastectomy in breast cancer patients who test negative for BRCA mutations. Am J Surg. 2011; 202:298–302.
Article
24. Foster C, Evans DG, Eeles R, Eccles D, Ashley S, Brooks L, et al. Predictive testing for BRCA1/2: attributes, risk perception and management in a multi-centre clinical cohort. Br J Cancer. 2002; 86:1209–16.
Article
25. Padamsee TJ, Wills CE, Yee LD, Paskett ED. Decision making for breast cancer prevention among women at elevated risk. Breast Cancer Res. 2017; 19:34.
Article
26. Park SY, Kim Y, Kim S. Factors associated with the decision to undergo risk-reducing salpingo-oophorectomy among women at high risk for hereditary breast and ovarian cancer: a systematic review. Korean J Women Health Nurs. 2020; 26:285–99.
Article
27. Katapodi MC, Lee KA, Facione NC, Dodd MJ. Predictors of perceived breast cancer risk and the relation between perceived risk and breast cancer screening: a meta-analytic review. Prev Med. 2004; 38:388–402.
Article
28. Tilburt JC, James KM, Sinicrope PS, Eton DT, Costello BA, Carey J, et al. Factors influencing cancer risk perception in high risk populations: a systematic review. Hered Cancer Clin Pract. 2011; 9:2.
Article
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr